ERCC1 expression in diffuse large b-cell lymphoma patients treated with a cisplatin-based regimen : a brief communication

Abstract EN

There is growing interest in defining biomarkers that could predict response to different chemotherapeutic agents.

Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer.

As cisplatin-based regimens are frequently used in the salvage treatment of diffuse large B-cell lymphomas (DLBCL), a small pilot study was conducted to determine whether ERCC1 is expressed in this disease or not.

Out of seven patients examined, only one had a 25% ERCC1 expression, which could represent a tumour truly expressing this marker.

However, expression was not able to predict response to treatment.

It remains unclear whether ERCC1 could serve as a predictive marker for cisplatin in this disease requiring further studies.